Advertisement
Advertisement
U.S. Markets open in 4 hrs 21 mins
Advertisement
Advertisement
Advertisement
Advertisement

Kymera Therapeutics, Inc. (KYMR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
53.15-1.00 (-1.85%)
At close: 04:00PM EST
52.00 -1.15 (-2.16%)
After hours: 07:20PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close54.15
Open54.18
Bid52.00 x 800
Ask69.50 x 900
Day's Range52.84 - 55.35
52 Week Range29.93 - 91.92
Volume499,533
Avg. Volume309,857
Market Cap2.393B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est76.29
  • GlobeNewswire

    Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413

    WATERTOWN, Mass., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for its IRAKIMiD degrader, KT-413. “Now that the FDA has cleared our IND, we look forward to initiating our KT-413 Phase 1 study in pat

  • GlobeNewswire

    Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021

    WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced it will host a virtual R&D Day for analysts and investors that will be held on Thursday, December 16th from 8:30 a.m. to 11:00 a.m. ET. Kymera’s R&D Day will include presentations from Nello Mainolfi, PhD, Co-Founder, President and CEO; Jared Gollo

  • GlobeNewswire

    Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

    WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, taking place from November 10 - 14, 2021 in Washington, D.C. and virtually. The results reveal Kymera’s potent and s

Advertisement
Advertisement